N/A N=9 Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV
Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation
Alveolar Ridge Defect
Primary: Change in Horizontal Ridge Widths From Baseline to 6 Months — 2.61 mm
N/A N=517 Swedish Adjustable Gastric Banding Observational Cohort Study
Obesity, Morbid
Primary: Mean BMI Change — -9.03 kg/m^2
N/A N=150 Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
Aortic Aneurysm, Thoracic
Primary: Aneurysm Related Death — 4 participants
Phase 3 N=437 Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
Diarrhea · Clostridium Infections
Primary: The Incidence of Antibiotic-associated Diarrhea. — 216; 221 participants
Phase 2 N=124 PRM-151 in the Prevention of Scarring Following Trabeculectomy
Glaucoma
Primary: Safety of Subconjunctival Injection — 274; 220; 166; 113 Number of occurrences
N/A N=500 Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)
Cervical Degenerative Disc Disease
Primary: Overall Success — 137; 110; 28; 13 participants who are successes
N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Moderate to Severe Plaque Psoriasis
Primary: Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12 — -74.6 percent change
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
Phase 4 N=38 Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
Schizophrenia
Primary: Main Outcome Measure: The Change From Baseline to Week 8 on the SANS — 2.06; -2.11 Units on a scale
N/A N=40 Satellite™ PEEK Nucleus Replacement Retrospective Analysis
Degenerative Disc Disease, Lumbar · Disc Herniation, Lumbar
Primary: Health-related Quality of Life Using the Visual Analogue Scale for Back Pain — 5.5; 2.6; 2.2; 1.9 units on a scale
Phase 2 N=20 Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Erythematous Rosacea
Primary: Cmax - Maximum Systemic Concentration of Brimonidine — NA; NA pg/mL
Phase 2 N=903 An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Autism Spectrum Disorder (ASD) · Autism · Autistic Disorder
Primary: Number of Confirmed Social Responsiveness Scale (SRS) Responders — 517; 351 participants
Phase 3 N=1,681 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs): Overall Summary — 77.4; 58.4; 7.8; 7.8 percentage of participants
Phase 1 N=78 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Subjects With Drug Related Adverse Events — 7; 3; 4; 14 participants